Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/1078-0432.CCR-13-1333 http://scihub22266oqcxt.onion/10.1158/1078-0432.CCR-13-1333 C4834266!4834266!26819452     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Cancer+Res 2016 ; 22 (8): 1837-42 Nephropedia Template TP {{tp|p=26819452|t=2016. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer |pdf=|usr=}}{{26819452}} gab.com Text Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer JO: Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=26819452 #FOAvip IDH1 and IDH2 are homodimeric enzymes that catalyze the conversion of isocitrate to ?-ketoglutarate (?-KG) and concomitantly produce reduced nicotinamide adenine dinucleotide phosphate (NADPH) from NADP+. Mutations in the genes encoding IDH1 and IDH2 have recently been found in a variety of human cancers, most commonly glioma, acute myeloid leukemia (AML), chondrosarcoma, and intrahepatic cholangiocarcinoma. The mutant protein loses its normal enzymatic activity and gains a new ability to produce the ?oncometabolite? R(?)-2-hydroxyglutarate (2HG). 2-HG competitively inhibits ?-KG-dependent enzymes which play crucial roles in gene regulation and tissue homeostasis. Expression of mutant IDH impairs cellular differentiation in various cell lineages and promotes tumor development in cooperation with other cancer genes. First-generation inhibitors of mutant IDH have entered clinical trials and have shown encouraging results in patients with IDH2 mutant AML. This article summarizes recent progress in our understanding of the role of mutant IDH in tumorigenesis. Twit Text FOAVip Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer ????Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=26819452 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26819452 #FOAvip English Wikipedia <ref>{{Cite pmid|26819452}}</ref> Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer #MMPMID26819452 Clark O; Yen K; Mellinghoff IK Clin Cancer Res 2016[Apr]; 22 (8): 1837-42 PMID26819452show ga IDH1 and IDH2 are homodimeric enzymes that catalyze the conversion of isocitrate to ?-ketoglutarate (?-KG) and concomitantly produce reduced nicotinamide adenine dinucleotide phosphate (NADPH) from NADP+. Mutations in the genes encoding IDH1 and IDH2 have recently been found in a variety of human cancers, most commonly glioma, acute myeloid leukemia (AML), chondrosarcoma, and intrahepatic cholangiocarcinoma. The mutant protein loses its normal enzymatic activity and gains a new ability to produce the ?oncometabolite? R(?)-2-hydroxyglutarate (2HG). 2-HG competitively inhibits ?-KG-dependent enzymes which play crucial roles in gene regulation and tissue homeostasis. Expression of mutant IDH impairs cellular differentiation in various cell lineages and promotes tumor development in cooperation with other cancer genes. First-generation inhibitors of mutant IDH have entered clinical trials and have shown encouraging results in patients with IDH2 mutant AML. This article summarizes recent progress in our understanding of the role of mutant IDH in tumorigenesis. äMolecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer (epmc).pdf DeepDyve Pubget Overpricing